Indonesia vs Iran, Islamic Republic of: Share of S. aureus infections resistant to methicillin
Indonesia
35.2%
in 2022
Iran, Islamic Republic of
34.7%
in 2022
Indonesia rank
16th
Iran, Islamic Republic of rank
17th
Share of S. aureus infections resistant to methicillin over time
- Indonesia
- Iran, Islamic Republic of
How they compare
Indonesia currently reports 35.2% against 34.7% in Iran, Islamic Republic of, a difference of 0.5%.
The two have swapped places 2 times across 5 shared years of data; in 2018 it was Indonesia ahead.
Indonesia ranks 16th and Iran, Islamic Republic of ranks 17th of 45 countries.
Across the 2 decades both report, Indonesia averaged higher in 1 and Iran, Islamic Republic of in 1.
Head to head by decade
| Decade | Indonesia | Iran, Islamic Republic of | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 46.1% | 38.8% | 7.3% | Indonesia |
| 2020s | 36.4% | 37.2% | 0.8% | Iran, Islamic Republic of |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Indonesia or Iran, Islamic Republic of?
- Indonesia, at 35.2% against 34.7% in Iran, Islamic Republic of as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Indonesia and Iran, Islamic Republic of?
- 0.5%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Iran, Islamic Republic of?
- 5 years are reported by both, from 2018 to 2022.
- How do Indonesia and Iran, Islamic Republic of rank globally for share of s. aureus infections resistant to methicillin?
- Indonesia ranks 16th and Iran, Islamic Republic of ranks 17th of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).